Oralair

Allergen extract from pollen of Dactylis glomerata, Anthoxanthum odoratum, Lolium perenne, Poa pratensis, the active ingredient in Oralair, is a grass pollen allergen extract presented as a sublingual tablet for sublingual use. It treats seasonal allergic rhinitis and allergic rhinoconjunctivitis caused by grass pollen in patients with confirmed sensitivity.

GNH USA supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oralair is an allergen immunotherapy tablet that targets grass‑pollen‑driven allergic disease. - Seasonal allergic rhinitis: reduces nasal congestion, sneezing and itching during grass pollen season. - Allergic rhinoconjunctivitis: alleviates eye irritation and nasal symptoms linked to grass pollen exposure. - Long‑term disease modification: may decrease the need for symptomatic allergy medications over multiple pollen seasons.

Oralair may cause local and systemic reactions following sublingual administration.

Common Side Effects: - Oral itching or mild irritation at the site of tablet placement. - Throat discomfort or mild soreness. - Transient mouth swelling. - Mild gastrointestinal upset such as nausea. - Headache. - Mild fatigue.

Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction. - Severe throat swelling that interferes with breathing. - Persistent wheezing or bronchospasm. - Angio‑edema of the lips or face. - Cardiovascular symptoms such as hypotension. - Severe urticaria or widespread rash.

Before starting Oralair, patients should be evaluated for suitability and instructed on proper use. - Contraindication: Known severe allergy to any component of the tablet. - Medical review: Assess for uncontrolled asthma or recent severe allergic reactions. - Monitoring: Observe for at least 30 minutes after the first dose for any systemic reaction. - Pregnancy: Use only if the potential benefit outweighs risk; data are limited. - Breastfeeding: Caution advised; discuss with a healthcare professional. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Oralair has a low potential for drug‑drug interactions, but certain co‑medications may modify its safety profile.

Major Interactions (Avoid): - Beta‑beta‑lactam antibiotics: may increase risk of systemic allergic reactions. - ACE inhibitors: can exacerbate angio‑edema risk when combined with allergen exposure. - NSAIDs: may heighten the chance of severe oral itching and swelling.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of an allergic reaction, delaying detection. - Corticosteroids: concurrent use may alter immune response to the tablet. - Leukotriene receptor antagonists: monitor for additive respiratory symptoms.